Mediators of Inflammation
Volume 2015 (2015), Article ID 106863, 3 pages
http://dx.doi.org/10.1155/2015/106863

Editorial

Purinergic Signalling in Immune System Regulation in Health and Disease

Jean Sévigny,1,2 Mireia Martín-Satué,3,4 and Jesús Pintor⁵

¹Département de Microbiologie-Infectiologie et d’Immunologie, Faculté de Médecine, Université Laval, Québec City, QC, Canada G1V 0A6
²Centre de Recherche du CHU de Québec, QC, Canada G1V 4G2
³Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Universitat de Barcelona, 08907 L’Hospitalet de Llobregat, Spain
⁴Institut d’Investigació Biomèdica de Bellvitge, 08908 Barcelona, Spain
⁵Department of Biochemistry and Molecular Biology, Faculty of Optics, Universidad Complutense de Madrid, 28037 Madrid, Spain

Received 11 December 2014; Accepted 11 December 2014

Copyright © 2015 Jean Sévigny et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The concept of a purinergic signalling system was first proposed by Professor Geoffrey Burnstock over 30 years ago. This includes the cellular responses to purine nucleotides, such as ATP, and nucleosides, such as adenosine, that act as extracellular messengers playing a role through specific nucleotide and adenosine receptors in all systems. Indeed, in addition to their role in cellular metabolism, nucleotides as well as nucleosides are extracellular mediators that activate biological responses in all cells. Cells subjected to activation or shear or mechanical stress release nucleotides such as ATP, ADP, UTP, and UDP in large amounts. All cells can release nucleotides in a controlled fashion [1]. The mechanisms of nucleotide release have been the focus of intense research activities but are still not fully understood. While activated platelets and neurons release nucleotides by exocytosis, neutrophils, and T lymphocytes use pannexin-1 hemichannels for nucleotide efflux, some cells also constitutively release nucleotides.

Under normal conditions, blood levels of nucleotides are below 0.1 μM, the level resulting from cell release, degradation by ectonucleotidases and reuptake of nucleotides after dephosphorylation by these enzymes [2]. There are many sources of extracellular nucleotides. In the circulatory system, red blood cells are a major source of nucleotides. The dense granules of the platelets contain a phenomenal amount of ATP and ADP approaching 1 M concentration that are secreted by exocytosis during activation. Nucleotides, primarily ATP, can be released by the endothelial cells and the smooth muscles cells of vessel walls. Nucleotide release can be triggered by shear stress, hypoxia and cell breakdown. As cytosolic ATP concentration is about 5 mM, rupture of the plasma membrane causes an increase in nucleotide concentrations near the injured cells. These mechanisms represent only a few examples of nucleotide release. Cells thus release large amounts of ATP, in a controlled manner but also when a cell is injured or dies which is particularly relevant in situation of inflammation and/or diseases.

Once released, nucleotides activate ubiquitously expressed ligand-gated ionotropic P2X receptors (P2X1–7) and G-protein-coupled metabotropic P2Y receptors () [1]. In addition, the cysteinyl-leukotriene receptor-1 and receptor-2 (CysLT₁ and CysLT₂) and GPR17 can also respond to nucleotides. P2 receptor subtypes differ with respect to selectivity towards nucleotides. All P2X receptors are activated by ATP, P2Y₂ by ATP and UTP, P2Y₁, P2Y₁₂, and P2Y₁₃ by ADP, P2Y₄ by UTP, P2Y₆ by UDP (in mouse also by UTP [3]), P2Y₁₁ by ATP > ADP, and P2Y₁₄ by UDP-glucose. In addition, adenosine, which results from the complete dephosphorylation of ATP and ADP by ectonucleotidases, activates P1-type receptors, which divide into four types: A₁, , , and A₃. These receptors are widely distributed and their activation has already been demonstrated to modulate a myriad of biological responses.

The responses induced by nucleotides can be modulated by cell surface enzymes generically called ectonucleotidases. Among them, the members of the ectonucleoside triphosphate diphosphohydrolase family (E-NTPDases) [4, 5] which convert tri- and diphosphonucleosides (ATP, ADP) to their monophosphate derivative (AMP). The latter is further hydrolysed to adenosine by ecto-5′-nucleotidase (CD73). Several other enzymes also modulate nucleotide concentrations, namely, nucleotide pyrophosphatases/diphosphodiesterases and alkaline and acid phosphatases. P2 receptor signalling can also be influenced by the ectokinases, that is, ectonucleotide diphosphokinases and adenylate kinases, that interconvert and regenerate nucleotides, respectively [2]. Hydrolysis thus switches off the nucleotide signal and plays a role in adenosine formation. These enzymes thus control relative concentrations of each nucleotide and nucleoside and, accordingly, regulate their effects.

Since its discovery, purinergic signalling has been shown to mediate a wide range of functions in health and disease, important among them being immunomodulation and inflammation. Recent advances have been made in therapies using nucleotide-related drugs in a broad range of pathological conditions such as acute and chronic inflammatory diseases. In this special issue, which is dedicated to purinergic signalling in immune system regulation in health and disease, we present 9 research papers and 4 reviews. The papers deal with the following topics.

By catalyzing the hydrolysis of extracellular AMP to adenosine, ecto-5′-nucleotidase/CD73 was shown to control vascular permeability and immune responses. By using double knockout mice lacking CD73 and another AMP-degrading enzyme, prostatic acid phosphatase (PAP), G. G. Yegutkin et al. show that PAP may have a synergistic role together with CD73 in the immune system by contributing to the lymphoid purine homeostasis and balance of leukocyte subpopulations in the lymph nodes and thymus. However, the absence of PAP alone did not have any significant effects outside the thymus.

S. D. S. Oliveira et al. show that schistosomiasis reduces peritoneal macrophage P2X7 receptor signaling which correlate with increased levels of TGF-β1 in infected mice as well as with reduced cell surface expression of P2X7. The involvement of P2 receptors in chemotactic responses of fibroblasts in the context of regulation of inflammatory responses and tissue damage repair is addressed by M. Pimentel-Santillana et al. in a paper that demonstrates that Prostaglandin E₂ inhibits P2Y-dependent cell migration.

Data presented by L. Oliveira et al. with a rat model suggest that restoration of neuromuscular transmission and immune competence may be possible by targeting common adenosine deficits in patients with autoimmune myasthenia gravis. In another paper, C. Vieira at al. show that postinflammatory ileitis suppresses adenosine neuromodulatory control leading to acceleration of the gastrointestinal transit, which may last more than a week. In an attempt to identify biomarkers for endometriosis, an inflammatory estrogen-dependent complex disorder that is one of the principal causes of infertility in women, L. Texidó et al. demonstrate the presence of ectonucleotidase activities in the contents of endometriomas.

The contribution carried out by K. R. Higgins et al. indicates that the activation of a P2Y₂ receptor present in a human monocytic cell line (THP-1) is very efficient inducing the chemokine CCL2. The effect carried out by the purinergic agonists is as good as the one triggered by lipopolysaccharide. Moreover, these researchers have found that polymorphisms of the P2Y₂ receptors are important regarding the CCL2 secretion. In this sense, human macrophages expressing 312Ser-P2Y₂ displayed significant UTP-induced CCL2 secretion above background compared to 312Arg-P2Y₂ expressing macrophages.

Neuroinflammation in the central nervous system occurring during pathologies such as amyotrophic lateral sclerosis and multiple sclerosis is a severe problem associated with those pathologies. S. Amadio et al. studied the role of P2Y₁₂ receptors in the neuroinflammatory condition, mainly on ramified microglia and myelinated fibers from primary organotypic cerebellar cultures or tissue slices from rat striatum, cerebellum, and spinal cord from symptomatic animals. These authors suggest that the modulation of P2Y₁₂ expression might play a dual role as analytic marker of branched/surveillant microglia and demyelinating lesions and also that potentially could be a predictive value under neuroinflammatory conditions as those found in amyotrophic lateral sclerosis and multiple sclerosis.

Laser therapy, particularly low-level-laser therapy, is being used with success as a complementary treatment for inflammation and wound healing in the dermis. L. Wang et al. present a paper dealing with the effects of red-laser irradiation on extracellular ATP content of mast cells and dorsal root ganglia neurons. In this sense, the authors show that irradiation potentiates extracellular ATP presence in mast cells by promoting ATP synthesis and release, but on the contrary laser attenuates extracellular ATP amounts of dorsal root ganglia neurons by upregulating ecto-ATPase activity.

This issue also presents the following reviews. The review of F. Pedata et al. covers the role of the adenosine receptor in acute injury and neuroinflammation in brain ischemia. A. Guzman-Aranguez et al. review purinergic receptors in ocular inflammation pointing out to the use of purinergic agonists and antagonists as possible therapeutic targets for inflammatory eye disorders. In their review, P. J. Sáez et al. focus on the effects of different cytokines on the intercellular communication mediated by hemichannels and gap junction channels in antigen-presenting cells and their impact on purinergic signaling. Finally, A. R. Santiago et al. reviewed the role of the nucleoside adenosine in microglial proliferation, chemotaxis, and reactivity. The authors focused on the adenosine receptor and discuss its role in Parkinson’s and Alzheimer’s diseases as well as in glaucoma and diabetic retinopathy.

Although there is still much to learn about the precise role of the adenosine and P2 receptors in the immune system and in inflammation, there is now wider acceptance that adenosine and nucleotides have a real and important function in this regard. This timely collection of well-informed and insightful articles summarises where we are now and points the future directions we should take. As the purinergic field is growing rapidly and it is getting increasingly demanding to keep up with the literature, we hope that this special issue will not only be useful from this point of view but also will inspire new experiments that reveal further insights regarding adenosine and nucleotides in all the aspects related to inflammation and the immune system.

Acknowledgment

Jean Sévigny is a recipient of a “Chercheur National” Scholarship Award from the Fonds de Recherche du Québec—Santé (FRQS).

Jean Sévigny
Mireia Martín-Satué
Jesús Pintor

References

F. Kukulski, S. A. Lévesque, and J. Sévigny, “Impact of ectoenzymes on P2 and P1 receptor signaling,” Advances in Pharmacology, vol. 61, pp. 263–299, 2011.

G. G. Yegutkin, “Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities,” Critical Reviews in Biochemistry and Molecular Biology, vol. 49, no. 6, pp. 473–497, 2014.

G. Kauffenstein, A. Drouin, N. Thorin-Trescases et al., “NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse,” Cardiovascular Research, vol. 85, no. 1, pp. 204–213, 2010.

A. R. Beaudoin, J. Sévigny, and M. Picher, “ATP-diphosphohydrolases, apyrases, and nucleotide phosphohydrolases: biochemical properties and functions,” in Biomembranes: A Multi-Volume Treatise, A. G. Lee, Ed., vol. 5 of ATPases, pp. 369–401, JAI Press, Greenwich, Conn, USA, 1996.

S. C. Robson, J. Sévigny, and H. Zimmermann, “The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance,” Purinergic Signalling, vol. 2, no. 2, pp. 409–430, 2006.